1. Classification and Chemical Overview

Midazolam (marketed in Europe and internationally under the brand name Dormicum) is a short-acting imidazobenzodiazepine derivative possessing hypnotic, anxiolytic, sedative, anticonvulsant, and muscle-relaxant properties. Under the Anatomical Therapeutic Chemical (ATC) classification system, it is indexed under N05CD08.

Chemically designated as 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine, midazolam differs structurally from classic 1,4-benzodiazepines due to the incorporation of an imidazo ring fused to the benzodiazepine core. In United Kingdom and European pharmaceutical practice, Dormicum 7.5 mg is formulated as film-coated oral tablets (as midazolam maleate). Under the Human Medicines Regulations 2012, midazolam is classified as a Prescription Only Medicine (POM) and is controlled under Schedule 3 of the Misuse of Drugs Regulations 2001 (as amended).

2. Mechanism of Action and Pharmacodynamics

Midazolam acts as a high-affinity positive allosteric modulator at central nervous system FRENTEA​ receptor complexes. It selectively binds to the benzodiazepine binding site located at the interface between the $\alpha$ y γ2​ subunits of the ionotropic FRENTEA​ receptor.

Binding accelerates the frequency of GABA-gated chloride ion channel opening, facilitating chloride ion influx into the postsynaptic neuron. The resultant neuronal membrane hyperpolarisation inhibits action potential propagation across the reticular activating system, limbic system, and motor cortex.

Midazolam is characterised by a rapid onset of clinical effect due to its high lipophilicity at physiological pH, rendering it a potent hypnotic agent that shortens sleep onset latency, decreases nocturnal awakenings, and induces short-term anterograde amnesia.

3. Approved UK Clinical Indications and Therapeutic Scope

Licensing for oral midazolam (Dormicum 7.5 mg) includes:

• Insomnia: Short-term treatment of severe insomnia that is disabling or subjecting the individual to extreme distress.

• Pre-medication: Pre-operative or pre-procedural sedation prior to surgical or diagnostic interventions.

Note on 7.5 mg Dosage Strength: The 7.5 mg tablet is the standard initial oral dose for adults for hypnotic indications, taken immediately prior to retiring. In elderly, debilitated, or renal/hepatically impaired patients, an initial dose of 3.75 mg (half tablet) is recommended to prevent excessive sedation and motor impairment.

NICE & BNF Guidance Context: In line with UK national guidance on hypnotic prescribing, oral midazolam is restricted to short-term use (maximum 2 weeks). Non-pharmacological therapies (such as Cognitive Behavioural Therapy for Insomnia, CBT-I) should be employed as primary management. Oral midazolam is less frequently prescribed in UK primary care than alternative short-acting Z-drugs (e.g., zopiclone, zolpidem), but retains utility in specialist secondary care and surgical premedication pathways.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Midazolam is rapidly and completely absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations (Tmax​) are achieved within 30 to 60 minutes post-dose. Absolute oral bioavailability ranges between 30% and 50% due to significant presystemic (first-pass) hepatic and intestinal metabolism.

• Distribution: Midazolam is highly lipophilic and widely distributed throughout body tissues, with an apparent volume of distribution (Vd​) at steady state of $0.7\text{ to }1.2\text{ L/kg}$. Plasma protein binding is high (approximately 96% to 98%), bound predominantly to albumin. Midazolam readily crosses the blood-brain barrier, placental barrier, and partitions into breast milk.

• Biotransformation: Midazolam undergoes extensive Phase I hepatic oxidation mediated predominantly by Cytochrome P450 3A4 (CYP3A4) and CYP3A5 isoenzymes. The primary active metabolite is 1′-hydroxymidazolam (alpha-hydroxymidazolam), which possesses approximately 10% of the pharmacological activity of the parent compound and is rapidly conjugated via glucuronidation.

• Elimination: Following hepatic metabolism and glucuronidation, approximately 60% to 80% of the dose is excreted in urine as 1′-hydroxymidazolam glucuronide, with less than 1% excreted unchanged. Systemic clearance is high ($300\text{ to }500\text{ mL/min}$). The elimination half-life (t1/2​) of midazolam is short, ranging between 1.5 and 2.5 hours. The active metabolite half-life is less than 1 hour.

5. Physiological Effects and Adverse Event Spectrum

Midazolam depresses central nervous system pathways, leading to rapid induction of sleep, reduced emotional reactivity, muscle relaxation, anterograde amnesia, and temporary decrements in psychomotor performance and respiratory drive.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Somnolence, daytime sedation, drowsiness, headache.

• Common ($\ge 1/100$ to $<1/10$): Confusion, dizziness, ataxia, lightheadedness, dysarthria, anterograde amnesia, visual disturbances, muscle weakness, fatigue, nausea, vomiting.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Hypersensitivity reactions, skin rash, urticaria, gastrointestinal disturbance, mood changes, libido fluctuations.

• Rare ($\ge 1/10,000$ to $<1/1,000$): Respiratory depression, apnoea, bronchospasm, hypotension, bradycardia, jaundice, urinary retention, blood dyscrasias, paradoxical reactions (such as acute agitation, restlessness, hyperactivity, aggressiveness, and hallucinations).

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindicaciones

• Hypersensitivity to midazolam, benzodiazepines, or formulation excipients.

• Severe respiratory insufficiency or acute respiratory depression.

• Myasthenia gravis.

• Severe sleep apnoea syndrome.

• Severe hepatic impairment (risk of precipitating hepatic encephalopathy).

• Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, HIV protease inhibitors).

Key Drug Interactions

• CYP3A4 Inhibitors: Concomitant administration with strong or moderate CYP3A4 inhibitors (e.g., azole antifungals, erythromycin, clarithromycin, diltiazem, verapamil, grapefruit juice) markedly increases midazolam plasma concentrations and elimination half-life, causing severe, prolonged sedation and respiratory depression.

• CYP3A4 Inducers: Co-administration with CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, St John’s Wort) drastically increases midazolam clearance, leading to marked loss of clinical efficacy.

• CNS Depressants & Alcohol: Concomitant administration with opioids, sedatives, hypnotics, antipsychotics, or alcohol produces additive CNS depression, severe hypotension, respiratory depression, coma, and death.

• Opioids: Combined use elevates the risk of profound respiratory depression and fatal overdose; prescribing must be limited to cases where non-sedating options are inadequate.

Clinical Precautions and Monitoring

• Anterograde Amnesia & Duration of Sleep: Midazolam causes potent anterograde amnesia. Patients must ensure they can have an uninterrupted sleep period of 7 to 8 hours following ingestion to minimise amnesic episodes and daytime incoordination.

• Dependence, Tolerance, and Withdrawal: Physical and psychological dependence can develop rapidly, even within short treatment durations. Abrupt cessation can trigger withdrawal symptoms, including rebound insomnia, anxiety, tremor, sweating, and convulsions. Tapering is mandatory following repeated administration.

• Elderly & Debilitated Patients: Heightened central sensitivity and decreased clearance increase the incidence of ataxia, confusion, and falls. Reduced initial dosing (3.75 mg) is mandatory.